01:20 PM EDT, 08/09/2024 (MT Newswires) -- Akero Therapeutics ( AKRO ) shares were down more than 4% in recent Friday trading after the company reported a wider Q2 loss.

The company widened its Q2 diluted loss to $0.81 per share, compared with a loss of $0.60 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.89.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, the company said it had $848.3 million in cash and or cash equivalents on hand, and expected it could fund operations through H2 2027 and fund the phase 3 studies of its drug candidates.

Price: 23.81, Change: -1.12, Percent Change: -4.49